INTRODUCTION: Chronic, non-healing wounds are often characterised by an excessive, and detrimental, inflammatory response. We review our experience of using a combined topical steroid, antibiotic and antifungal preparation in the treatment of chronic wounds displaying abnormal and excessive inflammation. METHODS: A retrospective review was undertaken of all patients being treated with a topical preparation containing a steroid (clobetasone butyrate 0.05%), antibiotic and antifungal at a tertiary wound healing centre over a ten-year period. Patients were selected as the primary treating physician felt the wounds were displaying excessive inflammation. Healing rates were calculated for before and during this treatment period for each patient. Changes in symptom burden (pain, odour and exudate levels) following topical application were also calculated. RESULTS: Overall, 34 ulcers were identified from 25 individual patients (mean age: 65 years, range: 37-97 years) and 331 clinic visits were analysed, spanning a total time of 14,670 days (7,721 days 'before treatment' time, 6,949 days 'during treatment' time). Following treatment, 24 ulcers demonstrated faster rates of healing, 3 ulcers showed no significant change in healing rates and 7 were healing more slowly (p=0.0006). Treatment generally reduced the burden of pain and exudate, without affecting odour. CONCLUSIONS: In normal wound healing, inflammation represents a transient but essential phase of tissue repair. In selected cases, direct application of a steroid containing agent has been shown to improve healing rates, presumably by curtailing this phase. Further evaluation is required to establish the role of preparations containing topical steroids without antimicrobials in the management of chronic wounds.
INTRODUCTION: Chronic, non-healing wounds are often characterised by an excessive, and detrimental, inflammatory response. We review our experience of using a combined topical steroid, antibiotic and antifungal preparation in the treatment of chronic wounds displaying abnormal and excessive inflammation. METHODS: A retrospective review was undertaken of all patients being treated with a topical preparation containing a steroid (clobetasone butyrate 0.05%), antibiotic and antifungal at a tertiary wound healing centre over a ten-year period. Patients were selected as the primary treating physician felt the wounds were displaying excessive inflammation. Healing rates were calculated for before and during this treatment period for each patient. Changes in symptom burden (pain, odour and exudate levels) following topical application were also calculated. RESULTS: Overall, 34 ulcers were identified from 25 individual patients (mean age: 65 years, range: 37-97 years) and 331 clinic visits were analysed, spanning a total time of 14,670 days (7,721 days 'before treatment' time, 6,949 days 'during treatment' time). Following treatment, 24 ulcers demonstrated faster rates of healing, 3 ulcers showed no significant change in healing rates and 7 were healing more slowly (p=0.0006). Treatment generally reduced the burden of pain and exudate, without affecting odour. CONCLUSIONS: In normal wound healing, inflammation represents a transient but essential phase of tissue repair. In selected cases, direct application of a steroid containing agent has been shown to improve healing rates, presumably by curtailing this phase. Further evaluation is required to establish the role of preparations containing topical steroids without antimicrobials in the management of chronic wounds.
Authors: Glenn P Ladwig; Martin C Robson; Ran Liu; M Ann Kuhn; David F Muir; Gregory S Schultz Journal: Wound Repair Regen Date: 2002 Jan-Feb Impact factor: 3.617
Authors: S E Dowd; J Delton Hanson; E Rees; R D Wolcott; A M Zischau; Y Sun; J White; D M Smith; J Kennedy; C E Jones Journal: J Wound Care Date: 2011-01 Impact factor: 2.072
Authors: Stefano Veraldi; Anna Maria Tortorano; Luisa Lunardon; Maria Chiara Persico; Claudia Francia Journal: Wounds Date: 2008-09 Impact factor: 1.546
Authors: Brian M Peters; Mary Ann Jabra-Rizk; Graeme A O'May; J William Costerton; Mark E Shirtliff Journal: Clin Microbiol Rev Date: 2012-01 Impact factor: 26.132
Authors: Matthew Cardinal; Tania Phillips; David E Eisenbud; Keith Harding; Jonathan Mansbridge; David G Armstrong Journal: BMC Dermatol Date: 2009-03-31
Authors: Ewa A Burian; Lubna Sabah; Tonny Karlsmark; Klaus Kirketerp-Møller; Christine J Moffatt; Jacob P Thyssen; Magnus S Ågren Journal: Int J Mol Sci Date: 2022-06-10 Impact factor: 6.208